Rchr
J-GLOBAL ID：202101001624004833
Update date: Jan. 31, 2024
MATSUDA Eriko
マツダ エリコ | MATSUDA Eriko
Affiliation and department：
Research theme for competitive and other funds (4)：
- 2023 - 2026 1型糖尿病の残存β細胞を保護・増殖するin vivo遺伝子治療の開発
- 2023 - 2026 浸潤・転移の骨軟部肉腫を治療可能な革新的な腫瘍溶解性ウイルス・免疫治療法の創出
- 2022 - 2025 免疫チェックポイントBispecific抗体遺伝子発現・腫瘍溶解性ウイルスの創出
- 2018 - 2021 Establishment of a new differentiation conversion method to mature pancreatic beta cells by analysis of gene expression over time during differentiation process
Papers (2)：
-
Eriko Matsuda, Yuki Obama, Ken-Ichiro Kosai. Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene therapy for type 1 diabetes in mice. Life sciences. 2021. 268. 119014-119014
-
Kaoru Mitsui, Tomoyuki Takahashi, Kanako Ide, Eriko Matsuda, Ken-Ichiro Kosai. Optimization of adenoviral gene transfer in human pluripotent stem cells. Biochemical and biophysical research communications. 2021. 541. 78-83
Association Membership(s) (2)：
Return to Previous Page
